Metabolomic profiling of CSF in multiple sclerosis and neuromyelitis optica spectrum disorder by nuclear magnetic resonance

PLoS ONE

Volumn 12, Issue 7, 2017, Pages

  Kim, Hyun Hwi ^a   Jeong, In Hye ^b   Hyun, Ja Shil ^a   Kong, Byung Soo ^b   Kim, Ho Jin ^b   Park, Sung Jean ^a  

^a Gachon University   (South Korea)

^b National Cancer Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYBUTYRIC ACID; ACETIC ACID; ACETONE; BUTYRIC ACID; CITRIC ACID; FORMIC ACID; GLUCOSE; ISOLEUCINE; LACTIC ACID; PYROGLUTAMIC ACID; UNCLASSIFIED DRUG; VALINE; 2-HYDROXYBUTYRIC ACID; ACETIC ACID DERIVATIVE; FORMIC ACID DERIVATIVE; HYDROXYBUTYRIC ACID;

ADOLESCENT; ADULT; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CHILD; CONTROLLED STUDY; DISEASE ACTIVITY; DOWN REGULATION; ENERGY METABOLISM; FATTY ACID SYNTHESIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLOMICS; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NEUROIMAGING; PROTON NUCLEAR MAGNETIC RESONANCE; AGED; CEREBROSPINAL FLUID; DIAGNOSTIC IMAGING; METABOLISM; METABOLOME; MIDDLE AGED; MULTIVARIATE ANALYSIS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROCEDURES; YOUNG ADULT;

ACETATES; ACETONE; ADOLESCENT; ADULT; AGED; CHILD; CITRIC ACID; FEMALE; FORMATES; GLUCOSE; HUMANS; HYDROXYBUTYRATES; LACTIC ACID; MAGNETIC RESONANCE SPECTROSCOPY; MALE; METABOLOME; METABOLOMICS; MIDDLE AGED; MULTIPLE SCLEROSIS; MULTIVARIATE ANALYSIS; NEUROMYELITIS OPTICA; PROTON MAGNETIC RESONANCE SPECTROSCOPY; PYRROLIDONECARBOXYLIC ACID; YOUNG ADULT;

EID: 85026216601     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0181758     Document Type: Article

References (78)

1. Vos T, Barber RM, Bell B, Bertozzi-Villa A, Biryukov S, Bolliger I, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. The Lancet. 2015; 386(9995):743–800.
2. McFarland HF, Martin R. Multiple sclerosis: a complicated picture of autoimmunity. Nature immunology. 2007; 8(9):913–919. https://doi.org/10.1038/ni1507 PMID: 17712344
3. Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. Nature Reviews Immunology. 2015; 15(9):545–558. https://doi.org/10.1038/nri3871 PMID: 26250739
4. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006; 66(10):1485–1489. https://doi.org/10.1212/01.wnl.0000216139.44259.74 PMID: 16717206
5. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. A serum autoanti-body marker of neuromyelitis optica: distinction from multiple sclerosis. The Lancet. 2004; 364 (9451):2106–2112.
6. Lennon VA, Kryzer TJ, Pittock SJ, Verkman A, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. The Journal of experimental medicine. 2005; 202(4):473–477. https://doi.org/10.1084/jem.20050304 PMID: 16087714
7. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. The Lancet Neurology. 2007; 6(9):805–815. https://doi.org/10.1016/S1474-4422(07)70216-8 PMID: 17706564
8. Kim HJ, Paul F, Lana-Peixoto MA, Tenembaum S, Asgari N, Palace J, et al. MRI characteristics of neuromyelitis optica spectrum disorder An international update. Neurology. 2015; 84(11):1165–1173. https://doi.org/10.1212/WNL.0000000000001367 PMID: 25695963
9. Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015; 85(2):177–189. https://doi.org/10.1212/WNL.0000000000001729 PMID: 26092914
10. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Annals of neurology. 2011; 69(2):292–302. https://doi.org/10.1002/ana.22366 PMID: 21387374
11. Kim S-H, Kim W, Li XF, Jung I-J, Kim HJ. Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder? Multiple Sclerosis Journal. 2012; 18(10):1480–1483. https://doi.org/10.1177/1352458512439439 PMID: 22354738
12. Min J-H, Kim BJ, Lee KH. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Multiple Sclerosis Journal. 2012; 18 (1):113–115. https://doi.org/10.1177/1352458511431973 PMID: 22146605
13. Dunn WB, Broadhurst DI, Atherton HJ, Goodacre R, Griffin JL. Systems level studies of mammalian metabolomes: the roles of mass spectrometry and nuclear magnetic resonance spectroscopy. Chemical Society Reviews. 2011; 40(1):387–426. https://doi.org/10.1039/b906712b PMID: 20717559
14. Emwas A-H, Luchinat C, Turano P, Tenori L, Roy R, Salek RM, et al. Standardizing the experimental conditions for using urine in NMR-based metabolomic studies with a particular focus on diagnostic studies: a review. Metabolomics. 2015; 11(4):872–894. https://doi.org/10.1007/s11306-014-0746-7 PMID: 26109927
15. Kumar D, Gupta A, Nath K. NMR-based metabolomics of prostate cancer: a protagonist in clinical diagnostics. Expert review of molecular diagnostics. 2016; 16(6):651–661. https://doi.org/10.1586/14737159.2016.1164037 PMID: 26959614
16. Emwas A-H, Roy R, McKay RT, Ryan D, Brennan L, Tenori L, et al. Recommendations and Standardization of Biomarker Quantification Using NMR-based Metabolomics with Particular Focus on Urinary Analysis. Journal of proteome research. 2016; 15(2):360–373. https://doi.org/10.1021/acs.jproteome.5b00885 PMID: 26745651
17. Chan AW, Mercier P, Schiller D, Bailey R, Robbins S, Eurich DT, et al. 1H-NMR urinary metabolomic profiling for diagnosis of gastric cancer. British journal of cancer. 2015; 114(1)59–62. https://doi.org/10.1038/bjc.2015.414 PMID: 26645240
18. Tian Y, Nie X, Xu S, Li Y, Huang T, Tang H, et al. Integrative metabonomics as potential method for diagnosis of thyroid malignancy. Scientific Reports. 2015; 5;14869. https://doi.org/10.1038/srep14869PMID: 26486570
19. Moussallieh F, Elbayed K, Chanson J, Rudolf G, Piotto M, De Seze J, et al. Serum analysis by 1H nuclear magnetic resonance spectroscopy: a new tool for distinguishing neuromyelitis optica from multiple sclerosis. Multiple Sclerosis Journal. 2014; 20(5):558–565. https://doi.org/10.1177/1352458513504638 PMID: 24080986
20. Sinclair AJ, Viant MR, Ball AK, Burdon MA, Walker EA, Stewart PM, et al. NMR-based metabolomic analysis of cerebrospinal fluid and serum in neurological diseases–a diagnostic tool? NMR in Biomedi-cine. 2010; 23(2):123–132. https://doi.org/10.1002/nbm.1428 PMID: 19691132
21. Mehrpour M, Kyani A, Tafazzoli M, Fathi F, Joghataie MT. A metabonomics investigation of multiple sclerosis by nuclear magnetic resonance. Magnetic Resonance in Chemistry. 2013; 51(2):102–109. https://doi.org/10.1002/mrc.3915 PMID: 23255426
22. Dickens AM, Larkin JR, Griffin JL, Cavey A, Matthews L, Turner MR, et al. A type 2 biomarker separates relapsing-remitting from secondary progressive multiple sclerosis. Neurology. 2014; 83(17):1492–1499. https://doi.org/10.1212/WNL.0000000000000905 PMID: 25253748
23. Tavazzi B, Batocchi AP, Amorini AM, Nociti V, D’Urso S, Longo S, et al. Serum metabolic profile in multiple sclerosis patients. Multiple sclerosis international. 2011; 2011:167156. https://doi.org/10.1155/2011/167156 PMID: 22096628
24. Simone IL, Federico F, Trojano M, Tortorella C, Liguori M, Giannini P, et al. High resolution proton MR spectroscopy of cerebrospinal fluid in MS patients. Comparison with biochemical changes in demyelinating plaques. Journal of the neurological sciences. 1996; 144(1):182–190.
25. Lutz NW, Viola A, Malikova I, Confort-Gouny S, Audoin B, Ranjeva J-P, et al. Inflammatory multiple-sclerosis plaques generate characteristic metabolic profiles in cerebrospinal fluid. PLoS One. 2007; 2 (7):e595. https://doi.org/10.1371/journal.pone.0000595 PMID: 17611627
26. W Lutz N, J Cozzone P. Metabolic profiling in multiple sclerosis and other disorders by quantitative analysis of cerebrospinal fluid using nuclear magnetic resonance spectroscopy. Current pharmaceutical biotechnology. 2011; 12(7):1016–1025. PMID: 21466459
27. Reinke S, Broadhurst D, Sykes B, Baker G, Catz I, Warren K, et al. Metabolomic profiling in multiple sclerosis: insights into biomarkers and pathogenesis. Multiple Sclerosis Journal. 2014; 20(10):1396–1400. https://doi.org/10.1177/1352458513516528 PMID: 24468817
28. Cocco E, Murgia F, Lorefice L, Barberini L, Poddighe S, Frau J, et al. 1H-NMR analysis provides a metabolomic profile of patients with multiple sclerosis. Neurology-Neuroimmunology Neuroinflammation. 2016; 3(1):e185. https://doi.org/10.1212/NXI.0000000000000185 PMID: 26740964
29. Gebregiworgis T, Nielsen HH, Massilamany C, Gangaplara A, Reddy J, Illes Z, et al. A Urinary Metabolic Signature for Multiple Sclerosis and Neuromyelitis Optica. Journal of proteome research. 2016; 15 (2):659–666. https://doi.org/10.1021/acs.jproteome.5b01111 PMID: 26759122
30. Xia J, Psychogios N, Young N, Wishart DS. MetaboAnalyst: a web server for metabolomic data analysis and interpretation. Nucleic acids research. 2009; 37(suppl 2):W652–W660. https://doi.org/10.1093/nar/gkp356 PMID: 19429898
31. Xia J, Sinelnikov IV, Han B, Wishart DS. MetaboAnalyst 3.0—making metabolomics more meaningful. Nucleic acids research. 2015; 43(W1):W251–W257. https://doi.org/10.1093/nar/gkv380 PMID: 25897128
32. Craig A, Cloarec O, Holmes E, Nicholson JK, Lindon JC. Scaling and normalization effects in NMR spectroscopic metabonomic data sets. Analytical chemistry. 2006; 78(7):2262–2267. https://doi.org/10.1021/ac0519312 PMID: 16579606
33. Stoyanova R, Brown T. NMR spectral quantitation by principal component analysis. NMR in Biomedi-cine. 2001; 14(4):271–277. PMID: 11410945
34. Trygg J, Holmes E, Lundstedt T. Chemometrics in metabonomics. Journal of proteome research. 2007; 6(2):469–479. https://doi.org/10.1021/pr060594q PMID: 17269704
35. Kullgren A, Samuelsson LM, Larsson DJ, Björnsson BT, Bergman EJ. A metabolomics approach to elucidate effects of food deprivation in juvenile rainbow trout (Oncorhynchus mykiss). American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. 2010; 299(6):R1440–R1448. https://doi.org/10.1152/ajpregu.00281.2010 PMID: 20861281
36. Wiklund S, Johansson E, Sjoestroem L, Mellerowicz EJ, Edlund U, Shockcor JP, et al. Visualization of GC/TOF-MS-based metabolomics data for identification of biochemically interesting compounds using OPLS class models. Analytical chemistry. 2008; 80(1):115–122. https://doi.org/10.1021/ac0713510PMID: 18027910
37. Worley B, Halouska S, Powers R. Utilities for quantifying separation in PCA/PLS-DA scores plots. Analytical biochemistry. 2013; 433(2):102–104. https://doi.org/10.1016/j.ab.2012.10.011 PMID: 23079505
38. Eriksson L, Trygg J, Wold S. CV-ANOVA for significance testing of PLS and OPLS® models. Journal of Chemometrics. 2008; 22(11-12):594–600.
39. Westerhuis JA, Hoefsloot HC, Smit S, Vis DJ, Smilde AK, van Velzen EJ, et al. Assessment of PLSDA cross validation. Metabolomics. 2008; 4(1):81–89.
40. Spurrier JD. On the null distribution of the Kruskal–Wallis statistic. Nonparametric Statistics. 2003; 15 (6):685–691.
41. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the royal statistical society Series B (Methodological). 1995:289–300.
42. Hajian-Tilaki K. Receiver operating characteristic (ROC) curve analysis for medical diagnostic test evaluation. Caspian journal of internal medicine. 2013; 4(2):627–635. PMID: 24009950
43. Wold S, Johansson E, Cocchi M. PLS-partial least squares projections to latent structures. 3D QSAR in drug design. 1993; 1:523–50.
44. Beal MF. Mitochondrial dysfunction in neurodegenerative diseases. Biochimica et Biophysica Acta (BBA)-Bioenergetics. 1998; 1366(1):211–223.
45. Ishibashi T, Dakin KA, Stevens B, Lee PR, Kozlov SV, Stewart CL, et al. Astrocytes promote myelination in response to electrical impulses. Neuron. 2006; 49(6):823–832. https://doi.org/10.1016/j.neuron.2006.02.006 PMID: 16543131
46. Zeis T, Allaman I, Gentner M, Schroder K, Tschopp J, Magistretti PJ, et al. Metabolic gene expression changes in astrocytes in Multiple Sclerosis cerebral cortex are indicative of immune-mediated signaling. Brain, behavior, and immunity. 2015; 48:313–325. https://doi.org/10.1016/j.bbi.2015.04.013 PMID: 25937052
47. Dutta R, McDonough J, Yin X, Peterson J, Chang A, Torres T, et al. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Annals of neurology. 2006; 59(3):478–489. https://doi.org/10.1002/ana.20736 PMID: 16392116
48. Dutta R, Trapp BD. Gene expression profiling in multiple sclerosis brain. Neurobiology of disease. 2012; 45(1):108–114. https://doi.org/10.1016/j.nbd.2010.12.003 PMID: 21147224
49. Jarius S, Paul F, Franciotta D, Ruprecht K, Ringelstein M, Bergamaschi R, et al. Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures. Journal of the neurological sciences. 2011; 306(1):82–90.
50. Jarius S, Wildemann B. Aquaporin-4 antibodies, CNS acidosis and neuromyelitis optica: A potential link. Medical hypotheses. 2013; 81(6):1090–1095. https://doi.org/10.1016/j.mehy.2013.10.011 PMID: 24182872
51. Nijland PG, Molenaar RJ, van der Pol SM, van der Valk P, van Noorden CJ, de Vries HE, et al. Differential expression of glucose-metabolizing enzymes in multiple sclerosis lesions. Acta neuropathologica communications. 2015; 3(79). https://doi.org/10.1186/s40478-015-0261-8 PMID: 26637184
52. Mathur D, López-Rodas G, Casanova B, Marti MB. Perturbed glucose metabolism: insights into multiple sclerosis pathogenesis. Front Neurol. 2014; 5:250. https://doi.org/10.3389/fneur.2014.00250 PMID: 25520698
53. Bélanger M, Allaman I, Magistretti PJ. Brain energy metabolism: focus on astrocyte-neuron metabolic cooperation. Cell metabolism. 2011; 14(6):724–738. https://doi.org/10.1016/j.cmet.2011.08.016 PMID: 22152301
54. Allaman I, Belanger M, Magistretti PJ. Methylglyoxal, the dark side of glycolysis. Front. Neurosci. 2015. https://doi.org/10.3389/fnins.2015.00023 PMID: 25709564
55. Fujihara K. Neuromyelitis optica and astrocytic damage in its pathogenesis. Journal of the neurological sciences. 2011; 306(1):183–187.
56. Gall WE, Beebe K, Lawton KA, Adam K-P, Mitchell MW, Nakhle PJ, et al. α-Hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population. PLoS One. 2010; 5 (5):e10883. https://doi.org/10.1371/journal.pone.0010883 PMID: 20526369
57. Tomiko K, Toshihiro S, Yoshito I, Masahiro M, Makoto Y, Yusuke S, et al. Studies of urinary organic acid profiles of a patient with dihydrolipoyl dehydrogenase deficiency. Clinica Chimica Acta. 1983; 133 (2):133–140.
58. Hoffmann G, Meier-Augenstein W, Stöckler S, Surtees R, Nyhan W. Physiology and pathophysiology of organic acids in cerebrospinal fluid. Journal of inherited metabolic disease. 1993; 16(4):648–669. PMID: 8412012
59. Paxton R, Scislowski P, Davis EJ, Harris RA. Role of branched-chain 2-oxo acid dehydrogenase and pyruvate dehydrogenase in 2-oxobutyrate metabolism. Biochemical Journal. 1986; 234(2):295–303. PMID: 3718468
60. von Morze C, Bok RA, Ohliger MA, Zhu Z, Vigneron DB, Kurhanewicz J. Hyperpolarized [13C] ketobuty-rate, a molecular analog of pyruvate with modified specificity for LDH isoforms. Magnetic resonance in medicine. 2016:1894–900.
61. Pettersen JE, Landaas S, Eldjarn L. The occurrence of 2-hydroxybutyric acid in urine from patients with lactic acidosis. Clinica Chimica Acta. 1973; 48(2):213–219.
62. Lassmann H, Van Horssen J, Mahad D. Progressive multiple sclerosis: pathology and pathogenesis. Nature Reviews Neurology. 2012; 8(11):647–656. https://doi.org/10.1038/nrneurol.2012.168 PMID: 23007702
63. Banerjee R, Zou C-g. Redox regulation and reaction mechanism of human cystathionine-β-synthase: a PLP-dependent hemesensor protein. Archives of Biochemistry and Biophysics. 2005; 433(1):144–156. https://doi.org/10.1016/j.abb.2004.08.037 PMID: 15581573
64. Calabrese V, Scapagnini G, Ravagna A, Bella R, Foresti R, Bates TE, et al. Nitric oxide synthase is present in the cerebrospinal fluid of patients with active multiple sclerosis and is associated with increases in cerebrospinal fluid protein nitrotyrosine and S-nitrosothiols and with changes in glutathione levels. Journal of neuroscience research. 2002; 70(4):580–587. https://doi.org/10.1002/jnr.10408PMID: 12404512
65. Calabrese V, Raffaele R, Cosentino E, Rizza V. Changes in cerebrospinal fluid levels of malondialde-hyde and glutathione reductase activity in multiple sclerosis. International journal of clinical pharmacology research. 1993; 14(4):119–123.
66. Kumar A, Bachhawat AK. Pyroglutamic acid: throwing light on a lightly studied metabolite. Curr Sci. 2012; 102(2):288–297.
67. Gnoni GV, Priore P, Geelen MJ, Siculella L. The mitochondrial citrate carrier: metabolic role and regulation of its activity and expression. IUBMB life. 2009; 61(10):987–994. https://doi.org/10.1002/iub.249PMID: 19787704
68. Iñarrea P, Alarcia R, Alava MA, Capablo JL, Casanova A, Iñiguez C, et al. Mitochondrial complex enzyme activities and cytochrome C expression changes in multiple sclerosis. Molecular neurobiology. 2014; 49(1):1–9. https://doi.org/10.1007/s12035-013-8481-z PMID: 23761047
69. Karelson G, Ziegler A, Künnecke B, Seelig J. Feeding versus infusion: a novel approach to study the NAA metabolism in rat brain. NMR in biomedicine. 2003; 16(6-7):413–423. https://doi.org/10.1002/nbm.845 PMID: 14679503
70. Moffett JR, Ross B, Arun P, Madhavarao CN, Namboodiri AM. N-Acetylaspartate in the CNS: from neu-rodiagnostics to neurobiology. Progress in neurobiology. 2007; 81(2):89–131. https://doi.org/10.1016/j.pneurobio.2006.12.003 PMID: 17275978
71. Chakraborty G, Mekala P, Yahya D, Wu G, Ledeen RW. Intraneuronal N-acetylaspartate supplies ace-tyl groups for myelin lipid synthesis: evidence for myelin-associated aspartoacylase. Journal of neuro-chemistry. 2001; 78(4):736–745. PMID: 11520894
72. Staffen W, Zauner H, Mair A, Kutzelnigg A, Kapeller P, Stangl H, et al. Magnetic resonance spectroscopy of memory and frontal brain region in early multiple sclerosis. The Journal of neuropsychiatry and clinical neurosciences. 2005; 17(3):357–363. https://doi.org/10.1176/jnp.17.3.357 PMID: 16179658
73. Kirov II, Tal A, Babb JS, Herbert J, Gonen O. Serial proton MR spectroscopy of gray and white matter in relapsing-remitting MS. Neurology. 2013; 80(1):39–46. https://doi.org/10.1212/WNL.0b013e31827b1a8c PMID: 23175732
74. Vingara LK, Yu HJ, Wagshul ME, Serafin D, Christodoulou C, Pelczer I, et al. Metabolomic approach to human brain spectroscopy identifies associations between clinical features and the frontal lobe metabolome in multiple sclerosis. Neuroimage. 2013; 82:586–594. https://doi.org/10.1016/j.neuroimage.2013.05.125 PMID: 23751863
75. Madhavarao CN, Arun P, Moffett JR, Szucs S, Surendran S, Matalon R, et al. Defective N-acetylaspartate catabolism reduces brain acetate levels and myelin lipid synthesis in Canavan’s disease. Proceedings of the National Academy of Sciences of the United States of America. 2005; 102(14):5221–5226. https://doi.org/10.1073/pnas.0409184102 PMID: 15784740
76. Wyss MT, Magistretti PJ, Buck A, Weber B. Labeled acetate as a marker of astrocytic metabolism. Journal of Cerebral Blood Flow & Metabolism. 2011; 31(8):1668–1674.
77. Calder PC. Branched-chain amino acids and immunity. The Journal of nutrition. 2006; 136(1):288S–293S.
78. Monirujjaman M, Ferdouse A. Metabolic and physiological roles of branched-chain amino acids. Advances in Molecular Biology. 2014; 2014:364976. https://doi.org/10.1155/2014/364976